THE TAPE
RCEL · Medical Instruments · $470.7M

Avita Medical, Inc. Common Stock

$15.22▼ −2.62%
Last close
Relative strength
99RS
of 99, against every stock• 0 on the month
Powering up
Front line
+176.8%
six months against Medical Instruments
52-week range
−17.4%
from the high
$3.22$18.43
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +53% on a year ago
Why it is on no screen

RCEL is off the screens on one check: shallow enough.

A base has formed22.8 weeks, from 3.53 to 5.92.
Long enough to count22.8 weeks against 3 needed.
Shallow enough40.4% deep against 35% allowed.
Close to its pivot+157.1% from the pivot; listed down to -20%.
Relative strengthRS 99 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$12.58
-17.3% · tested 3× · last 20 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Avita Medical, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 99, and it sits in Medical Instruments.

Against its industry
Front lineAhead of its industry over one, three and six months, in an industry fully aligned and ahead of the S&P 500.
One month against its industry
+12.1%
Three months against its industry
+54.3%
Six months against its industry
+176.8%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 21.1% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$84.7M
+53.1% year on year
Operating margin
-33.9%
gross 82.4%
Net margin
-42.7%
Free cash flow
$-20.2M
-4.3% of market cap
Price to sales
5.56×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$26.1M
+20.3% QoQ · +53.1% YoY
Gross margin
84.0%
+2.1 pts QoQ
Net income
−$6.2M
Loss
Free cash flow
−$821.0K
Burning · 13q runway

What the numbers say

  • Good: Revenue +53.1% year over year, +20.3% on the quarter
  • Good: Gross margin 84.0%, +2.1 points on the quarter
  • Weak: Net loss $6M, narrower than $8M last quarter
  • Weak: Burning cash: operating cash flow -$710K, free cash flow -$821K, better than -$4M last quarter · 13 quarters of cash at this burn
  • Weak: Growth externally funded: capex $111K against operating cash flow -$710K; share count +8.7% in a year
  • Net debt $35M · cash $10M
Revenue by quarter
Free cash flow
Net income
shares +8.7% in a year · net debt $35.0M

What is not obvious

  • Weak: Stock compensation $2M added back against negative operating cash flow
  • Weak: Interest $1M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $6M, narrower than $8M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Pulled back while its group leadsTape · 2026-11-14
3 lower closes in a leading group, 50d held, at 15.63
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
GappedTape · 2026-11-13
-6.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Red flag in a filingFiling · 2026-11-11
going concern
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).
New 52-week highTape · 2026-11-10
2.1x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-11-07
+5.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-07
+5.8% on earnings 2026-11-05
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-11-07
4.8 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
GappedTape · 2026-11-05
+6.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Avita Medical (RCEL) Upgraded to Buy: Here's What You Should KnowZacks Investment Research · 6 days agoAVITA Medical to Host Investor Webinar BriefingGlobeNewswire Inc. · 9 days ago

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

What analysts expect

No analyst coverage for this company. Most listed names have none, and an absence here is not a judgement about the business.

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Avita Medical, Inc. Common Stock (RCEL) — The Tape